← Leaderboards
Steven Kyle Grinspoon
Massachusetts General Hospital
$75,757,679
Attributed
$111,874,621
Total exposure
97
Grants
62
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $20.9M · FY2005–25$25M$18.8M$12.5M$6.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$126,718,108 · 98
By mechanism
U01$54,308,790 · 2
R01$25,966,270 · 6
P30$17,806,913 · 4
UG3$14,219,228 · 1
M01$11,438,323 · 81
K24$1,618,928 · 1
Top collaborators
- Pamela Susan Douglas13 shared
- Gail Kurr Adler5 shared
- Colleen M Hadigan3 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Hideo Makimura$795,960
- Matthias Nahrendorf$28,669,447
- Janet Lo$8,224,042
Others in their field
Top investigators on “Grant”
- David R. Weir · University Of Michigan At Ann Arbor$373,949,788
- David Heimbrook · Leidos Biomedical Research, Inc.$341,196,902
- Eric S Lander · Whitehead Institute For Biomedical Res$323,181,457
- Jeffrey P Krischer · University Of South Florida$258,583,867
- Lawrence Corey · Fred Hutchinson Cancer Center$253,286,867
- Barton F Haynes · Duke University$243,251,908
Research focus
GrantClinical ResearchResearch PersonnelBody CompositionHuman SubjectUnited States National Institutes Of HealthFundingHiv InfectionsObesityIndexingInflammationInflammatoryMetabolicAtherosclerosisHuman Therapy EvaluationCardiovascular Risk FactorResourcesBaseTestosteroneInstitutionSomatotropinLipodystrophyCardiovascular DiseasesHormone Regulation /Control Mechanism
Grant awards (200)
1/2 REPRIEVE Extension for Trial Completion$2,903,944
UG3 · FY2025 · HL · contact PI
Boston Area Nutrition Obesity Research Center (NORC)$1,258,933
P30 · FY2025 · DK · contact PI
Admin Core$268,849
P30 · FY2025 · DK · contact PI
2025 NORC Directors Meeting$83,767
P30 · FY2025 · DK · contact PI
1/2 REPRIEVE Extension for Trial Completion$4,747,407
UG3 · FY2024 · HL · contact PI
Nutrition Obesity Research Center at Harvard$1,258,933
P30 · FY2024 · DK · contact PI
Admin Core$268,849
P30 · FY2024 · DK · contact PI
1/2 REPRIEVE Extension for Trial Completion$6,567,877
UG3 · FY2023 · HL · contact PI
Nutrition Obesity Research Center at Harvard$1,260,282
P30 · FY2023 · DK · contact PI
INSPIRE- Inter-NORC SPeakIng ScholaR InitiativE$324,983
P30 · FY2023 · DK · contact PI
Admin Core$268,849
P30 · FY2023 · DK · contact PI
Nutrition Obesity Research Center at Harvard$1,308,585
P30 · FY2022 · DK · contact PI
Admin Core$268,849
P30 · FY2022 · DK · contact PI
Nutrition Obesity Research Center at Harvard$1,281,475
P30 · FY2021 · DK · contact PI
REPRIEVE - CCC - Lead Application$1,210,912
U01 · FY2021 · HL · contact PI
Admin Core$374,414
P30 · FY2021 · DK · contact PI
Nutrition Obesity Research Center at Harvard - Supplement for Director of the NORC Working Group on Workforce Diversity$65,841
P30 · FY2021 · DK · contact PI
Nutrition Obesity Research Center at Harvard$1,281,475
P30 · FY2020 · DK · contact PI
REPRIEVE COVID-19 Administrative Supplement$1,210,912
U01 · FY2020 · HL · contact PI
Effect of Mineralocorticoid Receptor Blockade on Coronary Vasculature and Myocardial Structure in HIV$699,184
R01 · FY2020 · DK · contact PI
Admin Core$374,414
P30 · FY2020 · DK · contact PI
Nutrition Obesity Research Center at Harvard$165,000
P30 · FY2020 · DK · contact PI
REPRIEVE - CCC - Lead Application$7,726,001
U01 · FY2019 · HL · contact PI
REPRIEVE - CCC - Lead Application$4,393,652
U01 · FY2019 · HL · contact PI
Nutrition Obesity Research Center at Harvard$1,284,763
P30 · FY2019 · DK · contact PI
Effect of Mineralocorticoid Receptor Blockade on Coronary Vasculature and Myocardial Structure in HIV$760,895
R01 · FY2019 · DK · contact PI
Admin Core$374,414
P30 · FY2019 · DK · contact PI
Nutrition Obesity Research Center at Harvard$128,604
P30 · FY2019 · DK · contact PI
Administrative Supplement to Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)$13,774,000
U01 · FY2018 · HL · contact PI
REPRIEVE - CCC - Lead Application$4,687,954
U01 · FY2018 · HL · contact PI
Nutrition Obesity Research Center at Harvard$1,291,599
P30 · FY2018 · DK · contact PI
Effect of Mineralocorticoid Receptor Blockade on Coronary Vasculature and Myocardial Structure in HIV$742,987
R01 · FY2018 · DK · contact PI
Admin Core$374,414
P30 · FY2018 · DK · contact PI
REPRIEVE - CCC - Lead Application$4,924,231
U01 · FY2017 · HL · contact PI
Nutrition Obesity Research Center at Harvard$1,337,275
P30 · FY2017 · DK · contact PI
Effect of Mineralocorticoid Receptor Blockade on Coronary Vasculature and Myocardial Structure in HIV$742,987
R01 · FY2017 · DK · contact PI
Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative U01 Grant$685,269
U01 · FY2017 · AI · contact PI
Admin Core$390,374
P30 · FY2017 · DK · contact PI
REPRIEVE - CCC - Lead Application$4,994,783
U01 · FY2016 · HL · contact PI
Nutrition Obesity Research Center at Harvard$1,255,986
P30 · FY2016 · DK · contact PI
Effect of Mineralocorticoid Receptor Blockade on Coronary Vasculature and Myocardial Structure in HIV$759,813
R01 · FY2016 · DK · contact PI
Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative U01 Grant$685,269
U01 · FY2016 · AI · contact PI
Training Program in Nutrition and Metabolism$132,884
T32 · FY2016 · HD · contact PI
Aldosterone Effects and Targeted Inhibition on Metabolic Indices in HIV-Infection$69,600
R01 · FY2016 · DK · contact PI
REPRIEVE - CCC - Lead Application$3,367,267
U01 · FY2015 · HL · contact PI
Nutrition Obesity Research Center at Harvard$1,255,986
P30 · FY2015 · DK · contact PI
Aldosterone Effects and Targeted Inhibition on Metabolic Indices in HIV-Infection$644,890
R01 · FY2015 · DK · contact PI
Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative U01 Grant$587,655
U01 · FY2015 · AI · contact PI
Training Program in Nutrition and Metabolism$124,550
T32 · FY2015 · HD · contact PI
Aldosterone Effects and Targeted Inhibition on Metabolic Indices in HIV-Infection$69,600
R01 · FY2015 · DK · contact PI
REPRIEVE - CCC - Lead Application$6,060,885
U01 · FY2014 · HL · contact PI
Aldosterone Effects and Targeted Inhibition on Metabolic Indices in HIV-Infection$644,890
R01 · FY2014 · DK · contact PI
Training Program in Nutrition and Metabolism$129,474
T32 · FY2014 · HD · contact PI
Inflammatory Mechanisms and Treatment Strategies for Atherosclerosis in HIV$967,884
R01 · FY2013 · HL · contact PI
Aldosterone Effects and Targeted Inhibition on Metabolic Indices in HIV-Infection$637,139
R01 · FY2013 · DK · contact PI
Training Program in Nutrition and Metabolism$134,785
T32 · FY2013 · HD · contact PI
Inflammatory Mechanisms and Treatment Strategies for Atherosclerosis in HIV$1,016,685
R01 · FY2012 · HL · contact PI
Aldosterone Effects and Targeted Inhibition on Metabolic Indices in HIV-Infection$680,540
R01 · FY2012 · DK · contact PI
Metabolic, and Cardiovascular Effects of GHRH in HIV Infected Patients$451,961
R01 · FY2012 · DK · contact PI
Strategies to Improve CAD Risk In HIV Disease$153,613
K24 · FY2012 · DK · contact PI
Training Program in Nutrition and Metabolism$77,148
T32 · FY2012 · HD · contact PI
Inflammatory Mechanisms and Treatment Strategies for Atherosclerosis in HIV$1,026,954
R01 · FY2011 · HL · contact PI
Aldosterone Effects and Targeted Inhibition on Metabolic Indices in HIV-Infection$703,123
R01 · FY2011 · DK · contact PI
Metabolic, and Cardiovascular Effects of GHRH in HIV Infected Patients$451,961
R01 · FY2011 · DK · contact PI
Strategies to Improve CAD Risk In HIV Disease$194,491
K24 · FY2011 · DK · contact PI
Inflammatory Mechanisms and Treatment Strategies for Atherosclerosis in HIV$806,397
R01 · FY2010 · HL · contact PI
Consequences and Treatment of Growth Hormone Deficiency in the Metabolic Syndrome$602,602
R01 · FY2010 · HL · contact PI
Metabolic Syndrome, Lifestyle Modification and Resistance Training in HIV Disease$462,888
R01 · FY2010 · DK · contact PI
Metabolic, and Cardiovascular Effects of GHRH in HIV Infected Patients$456,528
R01 · FY2010 · DK · contact PI
Strategies to Improve CAD Risk In HIV Disease$194,491
K24 · FY2010 · DK · contact PI
INITIATIVE TO DECREASE CARDIOVASCULAR RISK AND INCREASE QUALITY OF CARE$12,323
P41 · FY2010 · RR · contact PI
Inflammatory Mechanisms and Treatment Strategies for Atherosclerosis in HIV$805,830
R01 · FY2009 · HL · contact PI
Consequences and Treatment of Growth Hormone Deficiency in the Metabolic Syndrome$598,240
R01 · FY2009 · HL · contact PI
Metabolic Syndrome, Lifestyle Modification and Resistance Training in HIV Disease$467,563
R01 · FY2009 · DK · contact PI
Metabolic, and Cardiovascular Effects of GHRH in HIV Infected Patients$458,772
R01 · FY2009 · DK · contact PI
Training Program in Nutrition and Metabolism$194,244
T32 · FY2009 · HD · contact PI
Strategies to Improve CAD Risk In HIV Disease$193,458
K24 · FY2009 · DK · contact PI
INITIATIVE TO DECREASE CARDIOVASCULAR RISK AND INCREASE QUALITY OF CARE$3,840
P41 · FY2009 · RR · contact PI
Consequences and Treatment of Growth Hormone Deficiency in the Metabolic Syndrome$582,070
R01 · FY2008 · HL · contact PI
Metabolic Syndrome, Lifestyle Modification and Resistance Training in HIV Disease$467,563
R01 · FY2008 · DK · contact PI
Metabolic, and Cardiovascular Effects of GHRH in HIV Infected Patients$454,761
R01 · FY2008 · DK · contact PI
Strategies to Improve CAD Risk In HIV Disease$193,377
K24 · FY2008 · DK · contact PI
LONG-TERM PHYSIOLOGIC EFFECTS OF GH IN HIV LIPODYSTROPHY$186,658
M01 · FY2008 · RR · contact PI
LONG TERM EFFECTS OF TESTOSTERONE IN HIV-INFECTED WOMEN$172,122
M01 · FY2008 · RR · contact PI
Training Program in Nutrition and Metabolism$155,024
T32 · FY2008 · HD · contact PI
SUBCLINICAL ATHEROSCLEROSIS IN HIV INFECTED MEN$100,591
M01 · FY2008 · RR · contact PI
STRATEGIES FOR THE TREATMENT OF HIV ASSOCIATED METABOLIC SYNDROME$86,062
M01 · FY2008 · RR · contact PI
LONG-TERM PHYSIOLOGIC EFFECTS OF GH IN HIV LIPODYSTROPHY$78,236
M01 · FY2008 · RR · contact PI
ASSESSMENT OF CARDIOVASCULAR RISK IN HIV PATIENTS$54,765
M01 · FY2008 · RR · contact PI
METABOLIC EFFECTS OF SWITCHING KALETRA TO BOOSTED REYATAZ$54,765
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: 2MG DOSE OF TH9507, A GROWTH HORMONE RELEASING FACTOR ANALOG IN$50,296
M01 · FY2008 · RR · contact PI
SUBCLINICAL ALTHEROSCLEROSIS IN HIV INFECTED MEN$48,059
M01 · FY2008 · RR · contact PI
EFFECTS OF TNF-ALPHA ANTAGONISM IN PATIENTS WITH THE METABOLIC SYNDROME$30,758
M01 · FY2008 · RR · contact PI
LONG TERM EFFECTS OF TESTOSTERONE IN HIV-INFECTED WOMEN$27,941
M01 · FY2008 · RR · contact PI
STRATEGIES FOR THE TREATMENT OF HIV ASSOCIATED METABOLIC SYNDROME$16,765
M01 · FY2008 · RR · contact PI
ASSESSING THE SAFETY AND EFFICACY OF A 2MG DOSE OF TH9507, A GROWTH HORMONE RELE$15,649
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: USE OF TH9507 IN HIV INFECTED INDIVIDUALS WITH EXCESS ABDOMINAL$13,412
M01 · FY2008 · RR · contact PI
A MULTICENTER, DOUBLEBLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY ASSESSING THE$6,706
M01 · FY2008 · RR · contact PI
PREVALENCE AND METABOLIC CONSEQUENCES OF RELATIVE GROWTH HORMONE DEFICIENCY IN$1,457
M01 · FY2008 · RR · contact PI
LONG-TERM PHYSIOLOGIC EFFECTS OF GH IN HIV LIPODYSTROPHY$656,360
M01 · FY2007 · RR · contact PI
Consequences and Treatment of Growth Hormone Deficiency in the Metabolic Syndrome$577,199
R01 · FY2007 · HL · contact PI
Metabolic Syndrome, Lifestyle Modification and Resistance Training in HIV Disease$477,107
R01 · FY2007 · DK · contact PI
LONG TERM EFFECTS OF TESTOSTERONE IN HIV-INFECTED WOMEN$392,549
M01 · FY2007 · RR · contact PI
Physiologic Growth Hormone Effects in HIV Lipodystrophy$383,996
R01 · FY2007 · DK · contact PI
Androgen Effects in HIV-Infected Women$343,457
R01 · FY2007 · DK · contact PI
LONG-TERM PHYSIOLOGIC EFFECTS OF GH IN HIV LIPODYSTROPHY$227,931
M01 · FY2007 · RR · contact PI
Androgen Effects and Insulin Resistance in HIV Disease$146,170
K24 · FY2007 · DK · contact PI
USE OF TH9507 IN HIV INFECTED INDIVIDUALS WITH EXCESS ABDOMINAL FAT$135,068
M01 · FY2007 · RR · contact PI
EFFECTS OF LSM IN HIV AND METABOLIC SYNDROME$128,737
M01 · FY2007 · RR · contact PI
Training Program in Nutrition and Metabolism$128,085
T32 · FY2007 · HD · contact PI
THE EFFECTS OF NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTI) ON MITOCHOND$101,303
M01 · FY2007 · RR · contact PI
LONG TERM EFFECTS OF TESTOSTERONE IN HIV-INFECTED WOMEN$97,080
M01 · FY2007 · RR · contact PI
SUBCLINICAL ATHEROSCLEROSIS IN HIV INFECTED MEN$80,200
M01 · FY2007 · RR · contact PI
METABOLIC EFFECTS OF SWITCHING KALETRA TO BOOSTED REYATAZ$61,206
M01 · FY2007 · RR · contact PI
A MULTICENTER, DOUBLEBLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY ASSESSING THE$59,091
M01 · FY2007 · RR · contact PI
SUBCLINICAL ALTHEROSCLEROSIS IN HIV INFECTED MEN$37,989
M01 · FY2007 · RR · contact PI
EFFECTS OF A LIFESTYLE MODIFICATION PROGRAM (REACH) IN PATIENTS WITH HIV AND$29,549
M01 · FY2007 · RR · contact PI
ENDOCRINE FUNCTION, METABOLISM, AND BODY COMPOSITION IN WOMEN$2,108
M01 · FY2007 · RR · contact PI
EFFECTS OF TNF-ALPHA ANTAGONISM IN PATIENTS WITH THE METABOLIC SYNDROME$321
M01 · FY2007 · RR · contact PI
Metabolic Syndrome, Lifestyle Modification and Resistance Training in HIV Disease$510,107
R01 · FY2006 · DK · contact PI
LONG-TERM PHYSIOLOGIC EFFECTS OF GH IN HIV LIPODYSTROPHY$503,350
M01 · FY2006 · RR · contact PI
EFFECTS OF LSM IN HIV AND METABOLIC SYNDROME$398,909
M01 · FY2006 · RR · contact PI
Physiologic Growth Hormone Effects in HIV Lipodystrophy$395,465
R01 · FY2006 · DK · contact PI
Androgen Effects in HIV-Infected Women$353,715
R01 · FY2006 · DK · contact PI
LONG-TERM PHYSIOLOGIC EFFECTS OF GH IN HIV LIPODYSTROPHY$145,056
M01 · FY2006 · RR · contact PI
Androgen Effects and Insulin Resistance in HIV Disease$141,913
K24 · FY2006 · DK · contact PI
LONG TERM EFFECTS OF TESTOSTERONE IN HIV-INFECTED WOMEN$132,001
M01 · FY2006 · RR · contact PI
Training Program in Nutrition and Metabolism$127,460
T32 · FY2006 · HD · contact PI
THE EFFECTS OF NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTI) ON MITOCHOND$84,132
M01 · FY2006 · RR · contact PI
THE EFFECT OF TNF-ALPHA ANTAGONISM IN PATIENTS WITH METABOLIC SYNDROME$82,140
M01 · FY2006 · RR · contact PI
EFFECTS OF A LIFESTYLE MODIFICATION PROGRAM (REACH) IN PATIENTS WITH HIV AND$59,475
M01 · FY2006 · RR · contact PI
THE EFFECT OF TNF-ALPHA ANTAGONISM IN PATIENTS WITH METABOLIC SYNDROME$49,694
M01 · FY2006 · RR · contact PI
EXERCISE EFFECTS IN HIV-INFECTED WOMEN$47,869
M01 · FY2006 · RR · contact PI
ENDOCRINE FUNCTION, METABOLISM, AND BODY COMPOSITION IN WOMEN$40,615
M01 · FY2006 · RR · contact PI
LONG TERM EFFECTS OF TESTOSTERONE IN HIV-INFECTED WOMEN$37,716
M01 · FY2006 · RR · contact PI
MECHANISMS AND CLINICAL EFFECTS OF ADRENAL ANDROGEN SHUNTING IN HIV DISEASE$34,814
M01 · FY2006 · RR · contact PI
USE OF TH9507 IN HIV INFECTED INDIVIDUALS WITH EXCESS ABDOMINAL FAT$24,661
M01 · FY2006 · RR · contact PI
EXERCISE EFFECTS IN HIV-INFECTED WOMEN$10,153
M01 · FY2006 · RR · contact PI
A MULTICENTER, DOUBLEBLIND, RANCOMIZED, PLACEBO-CONTROLLED STUDY ASSESSING THE$8,703
M01 · FY2006 · RR · contact PI
MECHANISMS AND CLINICAL AFFECTS OF ADRENAL ANDROGEN SHUNTING IN HIV$2,903
M01 · FY2006 · RR · contact PI
ENDOCRINE FUNCTION, METABOLISM, & BODY COMPOSITION IN WOMEN W/AIDS LIPODYSTROPHY$1,449
M01 · FY2006 · RR · contact PI
Physiologic Growth Hormone Effects in HIV Lipodystrophy$404,982
R01 · FY2005 · DK
Androgen Effects in HIV-Infected Women$362,228
R01 · FY2005 · DK
MECHANISMS AND CLINICAL EFFECTS OF ADRENAL ANDROGEN SHUNTING IN HIV DISEASE$334,002
M01 · FY2005 · RR
EFFECTS OF LSM IN HIV AND METABOLIC SYNDROME$325,364
M01 · FY2005 · RR
LONG-TERM PHYSIOLOGIC EFFECTS OF GH IN HIV LIPODYSTROPHY$267,779
M01 · FY2005 · RR
Training Program in Nutrition and Metabolism$139,839
T32 · FY2005 · HD
Androgen Effects and Insulin Resistance in HIV Disease$137,779
K24 · FY2005 · DK
ENDOCRINE FUNCTION, METABOLISM, AND BODY COMPOSITION IN WOMEN$115,175
M01 · FY2005 · RR
THE EFFECT OF TNF-ALPHA ANTAGONISM IN PATIENTS WITH METABOLIC SYNDROME$99,453
M01 · FY2005 · RR
THE EFFECT OF TNF-ALPHA ANTAGONISM IN PATIENTS WITH METABOLIC SYNDROME$73,633
M01 · FY2005 · RR
EXERCISE EFFECTS IN HIV-INFECTED WOMEN$67,666
M01 · FY2005 · RR
LONG-TERM PHYSIOLOGIC EFFECTS OF GH IN HIV LIPODYSTROPHY$50,390
M01 · FY2005 · RR
EXERCISE EFFECTS IN HIV-INFECTED WOMEN$41,752
M01 · FY2005 · RR
EFFECTS OF A LIFESTYLE MODIFICATION PROGRAM (REACH) IN PATIENTS WITH HIV AND$37,433
M01 · FY2005 · RR
ENDOCRINE FUNCTION, METABOLISM, &BODY COMPOSITION IN WOMEN W/AIDS LIPODYSTROPHY$33,114
M01 · FY2005 · RR
HUMAN LEPTIN ADMINISTRATION ON NEUROENDOCRINE FUNCTION DURING FASTIN IN HUMANS$27,732
M01 · FY2005 · RR
LONG TERM EFFECTS OF TESTOSTERONE IN HIV-INFECTED WOMEN$27,352
M01 · FY2005 · RR
MECHANISMS AND CLINICAL AFFECTS OF ADRENAL ANDROGEN SHUNTING IN HIV$25,914
M01 · FY2005 · RR
LONG TERM EFFECTS OF TESTOSTERONE IN HIV-INFECTED WOMEN$15,838
M01 · FY2005 · RR
ASSESSMENT OF THE MECHANISMS AFFECTING GROWTH HORMONE IN HIV LIPODYSTROPHY$8,638
M01 · FY2005 · RR
EFFECTS OF RECOMBINANT HUMAN LEPTIN ADMINISTRATION ON NEUROENDOCRINE FUNCTION$1,912
M01 · FY2005 · RR
ASSESSMENT OF THE MECHANISMS AFFECTING GROWTH HORMONE IN HIV LIPODYSTROPHY$1,438
M01 · FY2005 · RR
THE USE OF GHRH IN THE AIDS LIPODYSTROPHY SYNDROME$571,419
M01 · FY2004 · RR
ASSESSMENT OF THE MECHANISMS AFFECTING GROWTH HORMONE IN HIV LIPODYSTROPHY$486,163
M01 · FY2004 · RR
MECHANISMS AND STRATEGIES FOR INSULIN RESISTANCE IN AIDS$423,072
R01 · FY2004 · DK
Physiologic Growth Hormone Effects in HIV Lipodystrophy$404,982
R01 · FY2004 · DK
Androgen Effects in HIV-Infected Women$362,228
R01 · FY2004 · DK
ENDOCRINE FUNCTION, METABOLISM, AND BODY COMPOSITION IN WOMEN$253,453
M01 · FY2004 · RR
HUMAN LEPTIN ADMINISTRATION ON NEUROENDOCRINE FUNCTION DURING FASTIN IN HUMANS$189,702
M01 · FY2004 · RR
EXERCISE EFFECTS IN HIV-INFECTED WOMEN$135,944
M01 · FY2004 · RR
Androgen Effects and Insulin Resistance in HIV Disease$133,766
K24 · FY2004 · DK
ENDOCRINE FUNCTION, METABOLISM, &BODY COMPOSITION IN WOMEN W/AIDS LIPODYSTROPHY$122,120
M01 · FY2004 · RR
THE USE OF GHRH IN THE AIDS LIPODYSTROPHY SYNDROME$110,597
M01 · FY2004 · RR
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ROSIGLITAZONE IN HIV$92,162
M01 · FY2004 · RR
EFFECTS OF LSM IN HIV AND METABOLIC SYNDROME$64,512
M01 · FY2004 · RR
EXERCISE EFFECTS IN HIV-INFECTED WOMEN$59,909
M01 · FY2004 · RR
ASSESSMENT OF THE MECHANISMS AFFECTING GROWTH HORMONE IN HIV LIPODYSTROPHY$50,688
M01 · FY2004 · RR
THE EFFECTS OF MENOPAUSE ON BONE DENSITY IN HIV-INFECTED WOMEN$36,863
M01 · FY2004 · RR
THE EFFECTS OF MENOPAUSE ON BONE DENSITY IN HIV-INFECTED$25,347
M01 · FY2004 · RR
EFFECTS OF RECOMBINANT HUMAN LEPTIN ADMINISTRATION ON N$19,358
M01 · FY2004 · RR
LONG-TERM PHYSIOLOGIC EFFECTS OF GH IN HIV LIPODYSTROPHY$16,126
M01 · FY2004 · RR
THE EFFECTS OF METFORMIN AND EXERCISE IN THE HIV LIPODYSTROPHY SYNDROME$9,214
M01 · FY2004 · RR
THE EFFECTS OF METFORMIN AND EXERCISE IN THE HIV LIPODYSTROPHY SYNDROME$4,611
M01 · FY2004 · RR
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF$2,629
M01 · FY2004 · RR
EFFECTS OF A LIFESTYLE MODIFICATION PROGRAM (REACH) IN$2,302
M01 · FY2004 · RR
MECHANISMS AND STRATEGIES FOR INSULIN RESISTANCE IN AIDS$423,072
R01 · FY2003 · DK
Androgen Effects in HIV-Infected Women$410,884
R01 · FY2003 · DK
Physiologic Growth Hormone Effects in HIV Lipodystrophy$404,982
R01 · FY2003 · DK
Androgen Effects and Insulin Resistance in HIV Disease$129,870
K24 · FY2003 · DK
MECHANISMS AND STRATEGIES FOR INSULIN RESISTANCE IN AIDS$427,452
R01 · FY2002 · DK
AIDS WASTING IN WOMEN--ANABOLIC EFFECTS OF TESTOSTERONE$401,870
R01 · FY2002 · DK
GONADAL PHYSIOLOGY AND SOMATOTROPH FUNCTION IN AIDS$200,768
M01 · FY2002 · RR
Growth Hormone Dynamics in AIDS Lipodystrophy$200,768
M01 · FY2002 · RR
Growth Hormone Dynamics in AIDS Lipodystrophy$200,768
M01 · FY2002 · RR
AIDS Wasting in Women--Testosterone Anabolic Effects$200,768
M01 · FY2002 · RR
AIDS Wasting in Women--Testosterone Anabolic Effects$200,768
M01 · FY2002 · RR
AIDS WASTING IN WOMEN--ANABOLIC EFFECTS OF TESTOSTERONE TREATMENT STUDY$200,768
M01 · FY2002 · RR
AIDS WASTING IN WOMEN--ANABOLIC EFFECTS OF TESTOSTERONE TREATMENT STUDY$200,768
M01 · FY2002 · RR
COMBINATION EXERCISE PLUS TESTOSTERONE IN EUGONADAL MEN WITH AIDS WASTING$200,768
M01 · FY2002 · RR